# US 2013/0156821 A1 · Solid ganaxolone formulations and methods for the making and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156821 A1
- Document ID: US20130156821A1
- Status: Published application
- Kind: A1
- Application number: 13/719,640
- Filed: 2012-12-19
- Published: 2013-06-20
- Earliest claimed: 2005-11-28
- Assignees: Marinus Pharmaceuticals
- Inventors: Kenneth SHAW; Mingbao ZHANG
- Web page: https://patentgrep.com/patent/US20130156821A1

## CPC

- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/143: {with inorganic compounds}
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/282: {Organic compounds, e.g. fats}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4891: {Coated capsules; Multilayered drug free capsule shells (with drug coating for immediate release A61K9/4808; osmotic devices A61K9/0004)}
- A61K 9/5078: {with drug-free core}
- A61K 9/5084: {Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs (tablets containing such a mixture A61K9/2077)}
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 47/02: Inorganic compounds
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- Y10S 977/773: Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y10S 977/775: Nanosized powder or flake, e.g. nanosized catalyst
- Y10S 977/906: Drug delivery
- Y10S 977/915: Therapeutic or pharmaceutical composition
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.

## Claims

### Claim at position 1

1-52. (canceled)

### Claim 53

A method of treating patients, comprising administering to human patients in need of treatment for a central nervous system disorder an effective amount of solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent which is a small organic molecule having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm and the concentration of ganaxolone in the solid stabilized particles is at least 50% by weight.

### Claim 54 (depends on 53)

The method of claim 53, wherein the hydrophilic polymer is in an amount from about 3% to about 50%, w/w, based on the weight of the solid particles.

### Claim 55 (depends on 54)

The method of claim 54, wherein the wetting agent is in an amount from about 0.01% to about 10%, w/w, based on the weight of the solid particles.

### Claim 56 (depends on 54)

The method of claim 54, wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.

### Claim 57 (depends on 53)

The method of claim 53, wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the formulation is dispersed in 15 mL of SGF or SIF at a concentration of 0.5 to 1 mg ganaxolone/mL as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.

### Claim 58 (depends on 53)

The method of claim 53, wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.

### Claim 59 (depends on 58)

The method of claim 58, wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour, as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.

### Claim 60 (depends on 53)

The method of claim 53 in the form of a powder.

### Claim 61 (depends on 53)

The method of claim 53, wherein the particles are incorporated into a dosage form selected from the group consisting of a tablet or capsule.

### Claim 62 (depends on 53)

The method of claim 53, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in distilled water is from about 100 nm to about 350 nm.

### Claim 63 (depends on 53)

The method of claim 53, wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, and pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 64 (depends on 53)

The method of claim 53, wherein the paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 65 (depends on 53)

The method of claim 53, wherein the hydrophilic polymer is selected from the group consisting of a cellulosic polymer, a vinyl polymer and mixtures thereof.

### Claim 66 (depends on 65)

The method of claim 65, wherein the cellulosic polymer is a cellulose ether.

### Claim 67 (depends on 65)

The method of claim 65, wherein the cellulose ether is hydroxypropymethylcellulose.

### Claim 68 (depends on 65)

The method of claim 65, wherein the vinyl polymer is polyvinyl alcohol.

### Claim 69 (depends on 53)

The method of claim 53, wherein the wetting agent is selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, and mixtures thereof.

### Claim 70 (depends on 53)

The method of claim 53, wherein the particles are incorporated into a solid dosage form, further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of an ionic dispersion modulator, an water soluble spacer, a disintegrant, a binder, a surfactant, a plasticizer, a lubricant, and any combinations or mixtures thereof.

### Claim 71 (depends on 70)

The method of claim 70, wherein the pharmaceutically acceptable excipient comprises an ionic dispersion modulator.

### Claim 72 (depends on 71)

The method of claim 71, wherein the ionic dispersion modulator is in an amount from about 1% to about 50%, w/w, based on the weight of the solid particles.

### Claim 73 (depends on 71)

The method of claim 71, wherein the ionic dispersion modulator is a salt.

### Claim 74 (depends on 71)

The method of claim 71, wherein the ionic dispersion modulator is an inorganic salt is selected from the group consisting of a magnesium salt, a calcium salt, a lithium salt, a potassium salt, a sodium salt and mixtures thereof.

### Claim 75 (depends on 71)

The method of claim 71, wherein the ionic dispersion modulator is an organic salt is selected from the group consisting of a citrate salt, a succinate salt, a fumarate salt, a malate salt, maleate salt, a tartrate salt, a glutarate salt, a lactate salt and mixtures thereof.

### Claim 76 (depends on 70)

The method of claim 70, wherein the pharmaceutically acceptable excipient comprises a water soluble spacer.

### Claim 77 (depends on 76)

The method of claim 76, wherein the water soluble spacer is in an amount from about 2% to about 60%, w/w, based on the weight of the solid particles.

### Claim 78 (depends on 189)

The method of claim 189, wherein the water soluble spacer is a saccharide or an ammonium salt.

### Claim 79 (depends on 78)

The method of claim 78, wherein the saccharide is selected from the group consisting of fructose, sucrose, glucose, lactose, mannitol and mixtures thereof.

### Claim 80 (depends on 70)

The method of claim 70, wherein the disintegrant is selected from the group consisting of cross-linked sodium carboxymethylcellulose, crospovidone and any combinations or mixtures thereof.

### Claim 81 (depends on 70)

The method of claim 70, wherein the surfactant is a polysorbate.

### Claim 82 (depends on 70)

The method of claim 70, wherein the plasticizer is polyethylene glycol.

### Claim 83 (depends on 53)

The method of claim 53, incorporated into a tablet or capsule, wherein the dosage form provides a ratio of mean blood plasma fed AUC(0-τ) to fasted AUC(0-τ) from about 1:1 to about 4:1.

### Claim 84 (depends on 53)

The method of claim 53, wherein the dosage form provides a ratio of mean blood plasma fed Cmax to fasted Cmax from about 1.5:1 to about 7:1.

### Claim 85 (depends on 53)

The method of claim 53, wherein the particles have a volume weighted median diameter (D50) from about 50 nm to about 1000 nm, and the dosage form provides a mean blood plasma AUC 0-24 hours from about 100 to about 375 ng*h/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fasted state.

### Claim 86 (depends on 53)

The method of claim 53, wherein the dosage form provides a mean blood plasma Cmax from about 25 to about 70 ng/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fasted state.

### Claim 87 (depends on 53)

The method of claim 53, wherein the dosage form providing a mean blood plasma AUC (0-48) hours from about 400 to about 1200 ng*h/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fed state.

### Claim 88 (depends on 53)

The method of claim 53, wherein the dosage form providing a mean blood plasma Cmax from about 60 to about 250 ng/ml when a dose of 200 mg to 500 mg of the ganaxolone is orally administered to adult subjects in the fed state.

### Claim 89 (depends on 53)

The method of claim 53, wherein the dosage form provides a mean blood plasma Cmax/Cmin ratio of not greater than about 4 to 1 at steady state with a dose of 200 to 500 mg ganaxolone to adult subjects in the fed or fasted state.

### Claim 90 (depends on 53)

The method of claim 53, wherein the solid dosage form is an immediate release dosage form.

### Claim 91 (depends on 53)

The method of claim 53, wherein the solid dosage form is a controlled release dosage form.

### Claim 92 (depends on 91)

The method of claim 91, wherein the particles are incorporated into an oral solid dosage form comprising (i) a controlled release component comprising a first portion of the stabilized particles; and a controlled release material, and (ii) an immediate release component comprising a second portion of the stabilized particles, the first and second portion of stabilized particles having a volume weighted median diameter (D50) of from about 50 nm to about 500 nm.

### Claim 93 (depends on 92)

The method of claim 92, wherein the ratio of ganaxolone in controlled release to immediate release is from about 4:1 to about 1:4.

### Claim 94 (depends on 91)

The method of claim 91, wherein dosage form provides a therapeutic effect for about 8 to about 24 hours after administration.

### Claim 95 (depends on 53)

The method of claim 53, wherein the complexing agent is in an amount from about 0.05% to about 5%, w/w, based on the weight of the solid particles.

### Claim 96 (depends on 53)

The method of claim 53, wherein the complexing agent comprises methylparaben or a salt thereof.

### Claim 97 (depends on 53)

The method of claim 53, wherein the complexing agent comprises benzoic acid or a salt thereof.

### Claim 98 (depends on 53)

The method of claim 53, wherein the complexing agent comprises methyl anthranilate.

### Claim 99 (depends on 53)

The method of claim 53, wherein the effective amount of solid stabilized particles include from about 200 mg to about 800 mg ganaxolone.

### Claim 100 (depends on 53)

The method of claim 53, further comprising incorporating the solid stabilized particles into an oral solid dosage form comprising from about 200 mg to about 800 mg ganaxolone prior to administration to said human patients.

### Claim 101

A method of treating patients, comprising administering to human patients in need of treatment for a central nervous system disorder an effective amount of solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent which is a small organic molecule having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm, the complexing agent being present in an amount from about 0.05% to about 5% w/w, based on the weight particles of the solid.

### Claim 102

A method of treating patients, comprising administering to human patients in need of treatment for a central nervous system disorder an effective amount of solid stabilized particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent selected from the group of small organic molecules having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, the stabilized particles having a volume weighted median diameter (D50) of the particles from about 50 nm to about 500 nm.

### Claim 103 (depends on 102)

The method of claim 102, wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.

### Claim 104 (depends on 100)

The method of claim 100, wherein the particles are incorporated into a dosage form selected from the group consisting of a tablet or capsule.

### Claim 105 (depends on 102)

The method of claim 102, wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, and pharmaceutically acceptable salts thereof and mixtures thereof.

### Claim 106 (depends on 105)

The method of claim 105, further comprising incorporating the solid stabilized particles into an oral solid dosage form comprising from about 200 mg to about 800 mg ganaxolone prior to administration to said human patients.
